Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

被引：3

作者：

Zhang, Hang ^{[1
]}

Zhang, Yingying ^{[2
]}

Zhu, Yingying ^{[3
]}

Dong, Tian ^{[1
]}

Liu, Zheng ^{[4
]}

机构：

[1] Sichuan Univ, Inst Hematol, Dept Hematol, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, Dept Neurol, West China Hosp, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, Chengdu, Peoples R China

[4] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

non-small cell lung cancer; targeted therapy; treatment response; drug resistance; tyrosine kinase inhibitor; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-III; POST-HOC ANALYSIS; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; DRUG-RESISTANCE; CRIZOTINIB RESISTANCE; INTEGRATED ANALYSIS;

D O I：

10.3389/fonc.2024.1387345

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer remains the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer with a generally poor prognosis. In recent years, advances in targeted therapy and sequencing technology have brought significant improvement in the therapeutic outcomes of patients with advanced NSCLC. Targeted inhibitors directed against specific mutated or rearranged oncogenes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and receptor tyrosine kinase ROS proto-oncogene 1(ROS1) among others, exhibit promising anti-tumor activity. Unfortunately, some patients develop acquired resistance and disease progression soon after initial remission. Despite the continuous development of new drugs and strategies to overcome drug resistance, it is still a major challenge in the treatment of NSCLC. The landscape of targeted therapy for NSCLC is evolving rapidly in response to the pace of scientific research. This study aimed to provide a comprehensive review of tumor target antigens and agents related to targeted therapy in NSCLC.

引用

页数：14

共 194 条

[1] Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient [J].

Ai, Xinghao ;

Niu, Xiaomin ;

Chang, Lianpeng ;

Chen, Rongrong ;

Ou, Sai-Hong Ignatius ;

Lu, Shun .

LUNG CANCER, 2018, 123 :83-86

[2] Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis [J].

Antonia, Scott J. ;

Borghaei, Hossein ;

Ramalingam, Suresh S. ;

Horn, Leora ;

De Castro Carpeno, Javier ;

Pluzanski, Adam ;

Burgio, Marco A. ;

Garassino, Marina ;

Chow, Laura Q. M. ;

Gettinger, Scott ;

Crino, Lucio ;

Planchard, David ;

Butts, Charles ;

Drilon, Alexander ;

Wojcik-Tomaszewska, Joanna ;

Otterson, Gregory A. ;

Agrawal, Shruti ;

Li, Ang ;

Penrod, John R. ;

Brahmer, Julie .

LANCET ONCOLOGY, 2019, 20 (10) :1395-1408

[3] Targeting BRAF-Mutant Non-Small Cell Lung Cancer: FromMolecular Profiling to Rationally Designed Therapy [J].

Baik, Christina S. ;

Myall, Nathaniel J. ;

Wakelee, Heather A. .

ONCOLOGIST, 2017, 22 (07) :786-796

[4] Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [J].

Ballard, Peter ;

Yates, James W. T. ;

Yang, Zhenfan ;

Kim, Dong-Wan ;

Yang, James Chih-Hsin ;

Cantarini, Mireille ;

Pickup, Kathryn ;

Jordan, Angela ;

Hickey, Mike ;

Grist, Matthew ;

Box, Matthew ;

Johnstrom, Peter ;

Varnas, Katarina ;

Malmquist, Jonas ;

Thress, Kenneth S. ;

Janne, Pasi A. ;

Cross, Darren .

CLINICAL CANCER RESEARCH, 2016, 22 (20) :5130-5140

[5] Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[6] Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety. [J].

Besse, Benjamin ;

Solomon, Benjamin J. ;

Felip, Enriqueta ;

Bauer, Todd Michael ;

Ou, Sai-Hong Ignatius ;

Soo, Ross A. ;

Camidge, D. Ross ;

Chiari, Rita ;

Gadgeel, Shirish M. ;

Riely, Gregory J. ;

Tan, Eng Huat ;

Hayashi, Hidetoshi ;

Mazieres, Julien ;

Thurm, Holger C. ;

Martini, Jean-Francois ;

Abbattista, Antonello ;

Peltz, Gerson ;

Clancy, Jill S. ;

Shaw, Alice Tsang .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9] Targeting RET-rearranged non-small-cell lung cancer: future prospects [J].

Bronte, Giuseppe ;

Ulivi, Paola ;

Verlicchi, Alberto ;

Cravero, Paola ;

Delmonte, Angelo ;

Crino, Lucio .

LUNG CANCER-TARGETS AND THERAPY, 2019, 10 :27-36

[10] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

← 1 2 3 4 5 6 7 8 9 10 →